The effectiveness of various treatments in reducing psychosomatic symptoms in patients with gastrointestinal dysfunction type D

The Effectiveness of Integrative Therapy, Acceptance and Commitment-Based Therapy, Short-term Psychoanalysis in Alexithymia, Distress and Psychosomatic Symptoms in Gastrointestinal Disorder Patients with High Score in the personality type D

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201107049294N1

Enrollment

Registered

2021-07-20

Start date

2020-09-05

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases of oesophagus, stomach and duodenum. Diseases of oesophagus, stomach and duodenum

Interventions

Intervention 1: Intervention group: First group therapy (integrated treatment).Integrated protocol by integrated protocol by Mollajafar et al. (2017) which is a combination of three therapies (cogniti

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patient cooperation to participate in the research complete the consent form First referral Minimum cycle education Age 60-18 years Patients with gastrointestinal dysfunction according to ROME III criteria by a gastroenterologist for patients referred to a psychiatric clinic Diagnosis of gastrointestinal dysfunction with irritable bowel syndrome (IBS) dyspepsia (FD) or both Do not take psychiatric drugs with the main purpose of reducing emotions (anxiety, etc.)

Exclusion criteria

Exclusion criteria: A history of substance abuse or dependence is currently on record during the four months prior to treatment Use of any type of psychiatric and psychiatric medication based on the record in the four months before the first treatment session Use of any kind of psychological and counseling services for any mental disorder I and II

Design outcomes

Primary

Measure	Time frame
Alexithymia. Timepoint: Before starting, after finishing, two months after finishing. Method of measurement: Toronto Alexithymia Scale.;Stress-Anxiety. Timepoint: Before starting, after finishing, two months after finishing. Method of measurement: DASS-21 Stress-Anxiety-Depression Inventory.;Psychosomatic Symptoms. Timepoint: Before starting, after finishing, two months after finishing. Method of measurement: Takata and Sakata Psychosomatic Complaints Scale.;Gastrointestinal Dysfunction. Timepoint: Before starting, after finishing, two months after finishing. Method of measurement: ROME-III questionnaire.	—

Measure

Time frame

Alexithymia. Timepoint: Before starting, after finishing, two months after finishing. Method of measurement: Toronto Alexithymia Scale.;Stress-Anxiety. Timepoint: Before starting, after finishing, two months after finishing. Method of measurement: DASS-21 Stress-Anxiety-Depression Inventory.;Psychosomatic Symptoms. Timepoint: Before starting, after finishing, two months after finishing. Method of measurement: Takata and Sakata Psychosomatic Complaints Scale.;Gastrointestinal Dysfunction. Timepoint: Before starting, after finishing, two months after finishing. Method of measurement: ROME-III questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Bakhshi

Islamic Azad University

ali_bakhshi110@yahoo.com+98 21 3305 5284

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026